LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Bridgebio Pharma Inc

Suletud

SektorTervishoid

38.57 0.6

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.16

Max

39.65

Põhinäitajad

By Trading Economics

Sissetulek

100M

-167M

Müük

111M

117M

Aktsiakasum

-0.989

Kasumimarginaal

-143.546

Töötajad

725

EBITDA

109M

-126M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+57.8% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-106M

6.7B

Eelmine avamishind

37.97

Eelmine sulgemishind

38.57

Uudiste sentiment

By Acuity

18%

82%

34 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Bridgebio Pharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. apr 2025, 09:30 UTC

Peamised uudised

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

12. sept 2024, 17:01 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12. sept 2024, 11:00 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Bridgebio Pharma Inc Prognoos

Hinnasiht

By TipRanks

57.8% tõus

12 kuu keskmine prognoos

Keskmine 60.5 USD  57.8%

Kõrge 95 USD

Madal 42 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Bridgebio Pharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

14

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

34.71 / 36.9Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

34 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.